New PET scan could replace biopsies for breast cancer patients
NCT ID NCT07294430
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a special PET scan that uses a radioactive tracer to track a protein called HER2 in the body. It aims to see if this imaging can predict how well a targeted cancer drug (T-DXd) works in 30 people with advanced breast cancer. The goal is to potentially replace invasive tumor biopsies with a simple scan.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
radioactive tracer [89Zr]-anti-HER2
What this could lead to
If successful, this imaging method could help doctors predict whether a targeted cancer drug is working without needing a tumor biopsy.
What could go wrong
This is a small, early-stage pilot study with only 30 participants, so results may not apply to all patients. The imaging technique is experimental and may not reliably predict treatment response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••